Balaxi Pharmaceuticals gets nod to invest up to $4 million in Balaxi Global FZCO
The Board of Directors of the company, in their meeting held on November 11, 2025, has approved the same
Balaxi Pharmaceuticals has received approval to invest up to $4 million as equity in its wholly owned subsidiary i.e Balaxi Global FZCO (Formerly known as Balaxi Global DMCC), Dubai. The objective for investment in WOS is to extend support for operational and business expansion requirements. The proposed investment would be completed on or before March 31, 2026.
The Board of Directors of the company, in their meeting held on November 11, 2025, has approved the same.
Balaxi Pharmaceuticals is engaged in the business of international wholesale trading of Pharmaceuticals, Builders Hardware and FMCG products.
